An FDA advisory panel found that Vanda Pharmaceuticals' (VNDA) tasimelteon, for the treatment of Non-24-Hour Disorder in the totally blind, appears to be safe and effective.
Vanda Pharmaceuticals was halted early Thursday morning and remained halted throughout the trading session. The stock is now up 2.74 on 226K shares after the bell.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.